YC
Therapeutic Areas
Scholar Rock Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Apitegromab (SRK-015) | Spinal Muscular Atrophy (Types 2 & 3) | Phase 3 |
| SRK-181 | Solid Tumors (Immuno-Oncology) | Phase 1 |
| SRK-439 | Obesity / Muscle Wasting | Preclinical |
| Drug | Indication | Phase |
|---|---|---|
| Apitegromab (SRK-015) | Spinal Muscular Atrophy (Types 2 & 3) | Phase 3 |
| SRK-181 | Solid Tumors (Immuno-Oncology) | Phase 1 |
| SRK-439 | Obesity / Muscle Wasting | Preclinical |